The Suzhou-based Xi’an Jiaotong-Liverpool University (XJTLU) and the UK’s University of Liverpool earlier this month held the inauguration of the Joint Centre for Pharmacology and Therapeutics. The Joint Center will allow scientists from both countries to carry out research into disease mechanisms and develop novel drugs for currently relevant diseases. The aim is to produce benefits for both the Suzhou region, including the nearby BioBAY industrial park, and the city of Liverpool.
Partners and Research Focus
The Joint Centre reportedly includes senior researchers from XJTLU, the Department of Pharmacology and Therapeutics from the University of Liverpool, Hengrui Pharmaceutical Co., Ltd (Shanghai), and Suzhou Guangji Psychiatric Hospital. The site will enable knowledge exchanges and talent cultivation between academic laboratories and both the pharma industry and clinical partners in terms of basic and clinical research on drug safety science, immuno-pharmacology, precision medicine, nanomedicine, and regulatory science.
Background on Partner Universities
The University of Liverpool’s pharmacology and toxicology research is recognized as world leading. Meanwhile, founded in 2006, XJTLU is an international joint university based in Suzhou, Jiangsu Province, produced from a partnership between the University of Liverpool and Xi’an Jiaotong University.-Fineline Info & Tech
